^
Association details:
Biomarker:No biomarker
Cancer:Peritoneal Cancer
Drug:Vegzelma (bevacizumab-adcd) (VEGF-A inhibitor)
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: A1 - Approval
New
Source:
Excerpt:
VEGZELMA is a vascular endothelial growth factor inhibitor indicated for the treatment of...Epithelial ovarian, fallopian tube, or primary peritoneal cancer...in combination with carboplatin and paclitaxel, followed by VEGZELMA as a single agent, for stage III or IV disease following initial surgical resection...in combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease who received no more than 2 prior chemotherapy regimens...in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by VEGZELMA as a single agent, for platinum-sensitive recurrent disease.
Secondary therapy:
gemcitabine + paclitaxel; carboplatin; paclitaxel + pegylated liposomal doxorubicin + topotecan